NCT03546192View on ClinicalTrials.gov

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 17, 2015

Primary Completion Date

July 17, 2015

Study Completion Date

July 17, 2015

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone Quadrivalent Influenza Vaccine

0.5-mL, Intramuscular, SH 2015 formulation

Trial Locations (3)

Unknown

Sanofi Pasteur Investigational Site 002, Manila

Sanofi Pasteur Investigational Site 003, Manila

Sanofi Pasteur Investigational Site 001, Quezon City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03546192 - Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route) | Biotech Hunter | Biotech Hunter